Use of beta-blockers and risk of contralateral breast cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Accepted author manuscript, 569 KB, PDF document
Beta-blockers have shown antineoplastic effects in laboratory studies but epidemiologic evidence in relation to contralateral breast cancer (CBC) is sparse. We investigated postdiagnosis beta-blocker use and risk of CBC in a cohort of 52 723 women with breast cancer by using nationwide Danish health registers and the Danish Breast Cancer Group database. We defined postdiagnosis beta-blocker use as a time-varying covariate starting 1 year after a second prescription was redeemed. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for CBC associated with beta-blocker use compared to nonuse. We identified 1444 women with CBC of whom 209 women were beta-blocker users. We found an overall HR of 1.08 (95% CI: 0.93-1.27) for beta-blocker use and risk of CBC with no substantial variation according to cumulative amount, intensity or selectivity of beta-blocker use. Hence, our cohort study of women with breast cancer did not sustain a protective effect of beta-blocker use on risk of CBC, irrespective of beta-blocker type.
Original language | English |
---|---|
Journal | International Journal of Cancer |
Volume | 150 |
Issue number | 10 |
Pages (from-to) | 1619-1626 |
ISSN | 0020-7136 |
DOIs | |
Publication status | Published - 2022 |
- beta-blockers, cancer prevention, contralateral breast cancer, pharmacoepidemiology
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
No data available
ID: 291533891